1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Epstein-Barr Virus-Associated Lymphoma: new trials by email Literature Review of Epstein-Barr Virus-Associated Lymphoma trials Research Report on Epstein-Barr Virus-Associated Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies VRx-3996 and valganciclovir - Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders | Phase 1 / Phase 2 | Completed | Viracta Therapeutics, Inc. | 64 | 2018-03-29 | 2025-03-20 |
Lymphoproliferative Disorders (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1)
2-(6-(((6-fluoroquinolin-2-yl)methyl)amino)bicyclo(3.1.0)hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (1) · Ganciclovir (1) · Valganciclovir (1)
Viracta Therapeutics, Inc. (1)
Brazil (1) · United States (1)